Our Posts

An Iowa couple has filed a lawsuit against Bayer HealthCare in the U.S. District Court of Southern Iowa, alleging serious injuries from the Essure birth control device. The wife reportedly suffered uterine perforation, liver enlargement, and infection, claiming Bayer failed to warn about these risks. The lawsuit accuses Bayer of negligence and not disclosing known complications to protect Essure's market value. The husband is also seeking damages for loss of consortium. The FDA has since added a "Black Box" warning to Essure due to safety concerns.

The bellwether trial concerning DePuy Orthopaedics' Pinnacle metal-on-metal hip implants has concluded its testimony phase and is now with the jury. The plaintiffs claim the implants caused severe complications, including pain, implant loosening, and metal poisoning. The trial featured expert testimony from surgeons and FDA consultants. The outcome may impact numerous pending cases. DePuy previously recalled a similar ASR hip implant and established a settlement program for affected recipients. Jury deliberations are ongoing following the dismissal of mistrial and JMOL motions.

The FDA has issued a warning about the risk of ketoacidosis linked to newer Type 2 diabetes medications, specifically SGLT2 inhibitors like canagliflozin, dapagliflozin, and empagliflozin. Ketoacidosis is a serious condition that can lead to hospitalization. Patients should watch for symptoms such as difficulty breathing and nausea and seek medical attention if they occur. The FDA is investigating and may update prescribing information. Patients should not alter their medication without consulting a doctor. Healthcare professionals should monitor for acidosis and discontinue SGLT2 inhibitors if confirmed.

Lawsuits against Bayer AG and Janssen Pharmaceuticals over the anticoagulant drug Xarelto highlight claims that the companies failed to warn about the risk of irreversible bleeding. Over 3,000 lawsuits have been filed, with 2,800 cases consolidated in a multidistrict litigation in Louisiana and 550 in a mass tort program in Philadelphia. Plaintiffs allege that Xarelto, approved to prevent blood clots, lacks a reversal agent for internal bleeding, unlike warfarin, which can be reversed with vitamin K. The litigation aims to address these safety concerns efficiently.

In 2017, the European Medicines Agency warned that SGLT2 inhibitors, including canagliflozin, dapagliflozin, and empagliflozin, used for type 2 diabetes, may increase the risk of lower limb amputations, particularly affecting the toes. Clinical trials, such as CANVAS and CANVAS-R, showed higher amputation rates in patients taking canagliflozin compared to a placebo. Patients are advised to monitor foot health closely. Although the exact cause of increased amputation risk is unknown, ongoing studies aim to provide more insights. Legal claims for drug injuries can involve manufacturing, design, or marketing defects.

The FDA is investigating Medline Remedy Essentials No-Rinse Cleansing Foam, linked to a Burkholderia cepacia outbreak in hospitals. This bacterium poses a risk to vulnerable patients, such as those with cystic fibrosis or weakened immune systems. The cleansing foam, used by patients unable to bathe with water, has led to 15 confirmed infections in California, New Jersey, and Pennsylvania. The FDA and CDC are examining the outbreak, and the recall may expand. Healthcare-associated infections remain a significant concern, affecting many patients annually in the U.S.

Proton pump inhibitors (PPIs), such as Nexium and Prilosec, may increase the risk of hip fractures in individuals over 50, according to research in the Journal of the American Medical Association. The study found a 44% higher risk for those using PPIs for over a year, with higher doses further increasing the risk. The reduced stomach acid from PPIs may hinder calcium absorption, affecting bone strength. Men were slightly more affected than women, possibly due to calcium supplement use. Experts recommend increasing calcium intake and engaging in weight-bearing exercises to mitigate risks.

The DePuy Pinnacle metal-on-metal hip implant has been linked to numerous painful side effects, leading to a surge in lawsuits. Patients expected improved mobility and pain relief but instead faced complications such as implant loosening, tissue damage, elevated metal ion levels, and severe pain. These issues often necessitated revision surgeries. The FDA reported significant adverse events related to the Pinnacle, with metal particles causing tissue reactions. Legal actions seek compensation for medical expenses due to these complications. Parker Waichman LLP offers legal assistance for affected individuals.

Parker Waichman LLP, a national law firm, is monitoring Xigduo XR, a diabetes medication by AstraZeneca, due to its potential side effects, including a risk of lactic acidosis and possible links to amputations. Although no specific cases of limb loss from Xigduo XR have been reported, the drug is under scrutiny. The FDA has required a Black Box Warning for lactic acidosis, but not for amputation risk. Parker Waichman LLP is prepared to assist clients seeking compensation for injuries related to SGLT2 drugs.

The Stöckert 3T heater-cooler system, used during surgeries to regulate body temperature, has been linked to Mycobacterium chimaera infections. The FDA and CDC have issued warnings about the risk of bacterial transmission through the device's exhaust. Lawsuits allege that LivaNova PLC failed to warn about these risks, with cases reported in several hospitals. Contamination was traced to manufacturing issues, resolved after September 2014. Patients exposed to the device may experience symptoms like night sweats and fatigue, and are advised to seek medical attention.

Parker Waichman LLP offers a complimentary case evaluation for individuals affected by Essure-related injuries. The firm is committed to helping clients secure compensation and is ready to investigate claims against Bayer, the manufacturer. It is important to act quickly to avoid losing legal rights. Contact Parker Waichman LLP at 1-800-YOURLAWYER (1-800-968-7529) or fill out their free consultation form to have an experienced attorney discuss your rights and claim options.

Parker Waichman LLP, a New York-based law firm, is investigating injury claims related to Gliflozin diabetes drugs, which have been linked to amputations and other severe side effects. The FDA warned in 2017 about the increased risk of lower limb amputations associated with these drugs, leading to lawsuits against manufacturers like Janssen Pharmaceuticals and AstraZeneca. The firm emphasizes the importance of choosing experienced legal representation to pursue compensation for injuries and economic damages. Parker Waichman LLP offers a proven track record and resources to handle complex litigation against major pharmaceutical companies.

Parker Waichman LLP offers free consultations for those seeking to file a hip replacement lawsuit. They emphasize the importance of timely action to secure your rights and pursue fair compensation without upfront costs. To get started, contact them at 1-800-YOURLAWYER (1-800-968-7529) or fill out their consultation form. An experienced Actemra lawyer will reach out to discuss your legal options and rights.

Since its FDA approval in 2011, Xarelto, a blood-thinning drug, has faced two black box warnings, the FDA's most serious label warnings. Despite its popularity over warfarin due to fewer restrictions, Xarelto lacks an antidote for bleeding episodes, leading to over 3,400 lawsuits against its manufacturers, Bayer AG and Janssen Pharmaceuticals. These lawsuits claim the companies failed to adequately warn users of the bleeding risks. Additionally, controversy surrounds the clinical trial data used for Xarelto's approval, raising concerns about dosing effectiveness and trial integrity.

The Medicines and Healthcare Products Regulatory Agency advises all metal-on-metal hip replacement recipients to schedule follow-up appointments to monitor for adverse soft tissue reactions, which can occur even in asymptomatic patients. Physiotherapists play a crucial role in early detection of muscle issues related to these implants. Research indicates improved outcomes for revision surgeries in the UK. However, complications such as metallosis and joint issues persist, leading to numerous lawsuits. The hope is for advancements in technology to enhance future hip replacement success.

The Mirena® IUD is a T-shaped contraceptive device that releases levonorgestrel to prevent pregnancy. It carries risks such as uterine perforation, embedment, migration, and the need for surgical removal. If pregnancy occurs with the IUD in place, there's a heightened risk of ectopic pregnancy. It may also increase the risk of pelvic inflammatory disease, leading to severe complications. Some users have reported group A streptococcal sepsis. There is ongoing investigation into a possible link with rheumatoid arthritis. Legal assistance is available for those affected.

In September 2017, DePuy, a Johnson & Johnson subsidiary, faced its first lawsuit over the Attune Knee System due to adhesion issues. The system's failure, primarily due to "tibial baseplate failure," prevents proper bonding with the patient's lower leg. A study in the Journal of Knee Surgery highlighted an unusually high early failure rate, with 232 FDA reports and additional hospital data indicating underreporting. Patients experience symptoms like pain and instability, often requiring complex revision surgeries. The exact number of affected implants is unclear, but the failure rate is concerning.

The Attune Knee System, produced by DePuy Synthes, has been reported to have high failure rates, leading to severe complications such as pain, infections, and the need for additional surgeries. These issues often arise from flawed bonding in the tibial component, causing loosening and other problems soon after surgery. Parker Waichman LLP is investigating these failures to help affected patients seek compensation. They offer free consultations for those experiencing complications from the Attune Knee System, emphasizing the importance of experienced legal representation in medical device litigation.

The Supreme Court of New Jersey has centralized all Mirena IUD litigation in Bergen County under Superior Court Judge Brian R. Martinotti. This decision aims to streamline the legal process due to the common allegations that the Mirena IUD, a birth control device approved by the FDA in 2000, can perforate the uterus and migrate, causing serious health issues. Plaintiffs claim Bayer, the manufacturer, failed to adequately warn about these risks. The litigation is supported by Parker Waichman LLP, with Matthew J. McCauley as senior litigation counsel.

Protonix, a proton pump inhibitor (PPI) manufactured by Pfizer, is used to treat gastrointestinal issues like heartburn and ulcers by reducing stomach acid production. While effective, long-term use can lead to serious side effects, including kidney damage and osteoporosis-related fractures. Protonix is available by prescription only, with pantoprazole as its generic form. Legal actions have been taken against Pfizer due to inadequate warnings about these risks. Individuals affected by Protonix may seek compensation through lawsuits, with legal assistance available for evaluating potential claims.

Thousands of patients, including Angie Rodriguez, claim serious injuries from DePuy Pinnacle metal-on-metal hip implants, alleging cobalt toxicity. These implants, never tested in humans, were marketed as safe despite warnings from surgeons about potential side effects. A lawsuit accuses DePuy of using patients as test subjects and paying doctors to promote the implants. In 2016, a $1.04 billion verdict was awarded against DePuy and Johnson & Johnson for failing to warn about risks. The FDA has since tightened regulations on such implants.

Bayer and Janssen Pharmaceuticals face scrutiny for allegedly failing to inform users of Xarelto's potential risks. By July 2016, nearly 6,000 lawsuits were filed against them. Concerns arose in September 2015 when faulty blood-testing data, used in a study, was submitted to the New England Journal of Medicine, influencing FDA approval. A 2013 article in the Journal of the American College of Cardiology highlighted data inconsistencies, questioning the drug's safety. The legal proceedings will determine if the companies prioritized financial interests over patient safety.

The DePuy Pinnacle metal-on-metal hip implants have been linked to the release of metal debris, potentially causing metal poisoning. Despite warnings from a consulting doctor in 2001, DePuy continued marketing the implants. Kathleen Herlihy-Paoli is suing the company, claiming her implants released cobalt and chromium, leading to severe complications. Reports indicate a 15% failure rate within five years, contrary to DePuy's marketing claims. Over 6,000 similar cases are pending, highlighting significant concerns about the safety and marketing of these implants.

Parker Waichman LLP is investigating claims related to the HIV drug Juluca, which may cause neural tube birth defects if used during early pregnancy. The FDA issued a safety notification in 2018 after a study linked Juluca to these defects. Women taking Juluca who are pregnant or planning pregnancy should consult their doctor. Legal claims consider the timing of Juluca use, diagnosis of birth defects, and other medications taken. Parker Waichman LLP offers free consultations to evaluate potential claims for compensation.